IP Library Granted Patent US 11,124,775
Granted Patent B2
US 11,124,775 · App. 15/574,337 · Granted Sep 21, 2021

Retroviral particle comprising at least two encapsidated nonviral RNAs

Inventors: Pascale Bouille (Vincennes, FR); Jean-Christophe Pages (Paris, FR); Régis Gayon (Ramonville Saint-Agne, FR)
Assignee: FLASH THERAPEUTICS
C12N7/00A61K48/0008C07K14/005C12N7/025C12N7/045C12N15/86A61K48/00C07K2319/85C12N2740/15021C12N2740/16042C12N2740/16051C12N2740/16052C12N2740/16071C12N2740/16222C12N2795/18152
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,124,775
App. No.
15/574,337
Granted
Sep 21, 2021
Kind
B2
Abstract

The present invention relates to a retroviral system for the transfer of non-viral RNA into target cells and more particularly a retroviral particle capable of delivering multiple RNAs. More particularly, it relates to retroviral particles comprising a protein derived from the Gag polyprotein an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest linked to an encapsidation sequence, each encapsidation sequence being recognised by a binding domain introduced into the protein derived from the Gag polyprotein and/or into the integrase.

Claims (12)

1. A retroviral particle comprising a protein from a Gag polyprotein, an envelope protein, optionally an integrase, and at least two encapsidated, different, non-viral RNAs, the at least two encapsidated, different, non-viral RNAs each comprising an RNA sequence of interest linked to an encapsidation sequence, each encapsidation sequence bound to a heterologous binding domain introduced into the protein from the Gag polyprotein.

2. The retroviral particle according to claim 1 , wherein the protein from the Gag polyprotein is a nucleocapsid protein.

3. The retroviral particle according to claim 2 , which is a lentiviral particle.

4. The retroviral particle which is a lentiviral particle according to claim 3 , wherein:

the binding domain is the Coat protein of bacteriophage MS2;

each of the encapsidation sequences of the non-viral RNAs is a stem-loop sequence of MS2; and

the nucleocapsid protein is the nucleocapsid protein (NC) of HIV, wherein the Coat protein is inserted at the second zinc finger of the NC.

5. The retroviral particle which is a lentiviral particle according to claim 3 , wherein:

the binding domain is the Coat protein of bacteriophage PP7;

each of the encapsidation sequences of the non-viral RNAs is a stem-loop sequence of PP7; and

the nucleocapsid protein is the nucleocapsid protein (NC) of HIV, wherein the Coat protein is inserted at the second zinc finger of the NC.

6. A composition comprising a plurality of the retroviral particle according to claim 1 .

Assignments (3)
CONFIRMATORY ASSIGNMENT Recorded Oct 25, 2024
From: FLASH THERAPEUTICS
To: IQ EQ MANAGEMENT
Reel/Frame 069241/0159 →
CHANGE OF NAME Recorded Mar 7, 2021
From: VECTALYS
To: FLASH THERAPEUTICS
Reel/Frame 055515/0300 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2017
From: BOUILLE, PASCALE; PAGES, JEAN-CHRISTOPHE; GAYON, RÉGIS
To: VECTALYS
Reel/Frame 044136/0631 →
Priority Claims (2)
FR 1554381 · May 15, 2015 · national
FR 1653280 · Apr 13, 2016 · national
Continuity (1)
Related Publication 20180135025A1 · May 17, 2018
Cited By (4)
US 12,319,938 US 12,351,814 US 12,351,815 US 12,404,525